Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions.
April 2, 2020
June 26, 2020
The majority of the Pharmetheus staff will continue working from home during the summer period. A new decision on continued travel restrictions will be taken in September.
Thank you for your collaboration!
Peter Milligan, CEO
Marie Sandström, COO
On behalf of the Pharmetheus Team
Latest news from Pharmetheus
Welcome Ninni Sylenius!
Welcome Viviana Moroso!
Welcome Mikael Ringh!
Pharmetheus presence at ISTH 2020 congress
Read more about our support to drug development of a recombinant von Willebrand factor in patients with severe von Willebrand disease (abstract numbers PB1541 and PB1544) and of dabigatran in children with venous thromboembolism (abstract numbers PB1271 and PB1272): https://www.isth2020.org/abstracts
New service: Quantitative Systems Pharmacology (QSP)
Congratulations Prof. Andrew Hooker!
Welcome Henrik Hellerstedt!
Covid-19 Pharmacology Resource
We have now joined the COVID-19 Pharmacology Resource Center. Conquering COVID-19 with clinical pharmacology, innovation, and collaboration.
More information available at the Covid-19 Pharmacology Resource web page
Pharmetheus Approach to COVID-19 related challenges in clinical trial conduct
Pharmetheus is currently working with a number of clients to address the impact of the current COVID-19 epidemic to their ongoing clinical drug development programs. We would like to share our high level approach with the community at large. We see the current situation as both a challenge to our industry/sector but also an opportunity for appropriate and quantitative approaches to mitigate upon these challenges. We believe there are "fit for purpose" options for a broad range of plausible scenarios in clinical trial conduct that have emerged or could emerge.
See our approach
Welcome Julie Janssen and Anna Pousette!
We are very happy to welcome two new team members, Julie Janssen, MIDD consultant, and Anna Pousette, Contracts Manager. Julie's research experience includes the application of pharmacometrics in the clinical setting, chemotherapy and targeted therapies, as well as special patient populations (e.g. pediatrics and pregnancy). Julie is based in the Netherlands. See Julie's bio here. Anna has long experience of project coordination and procurement. Anna will work from our Uppsala office in Sweden. See Anna's bio here.
Open Systems Pharmacology publication
PBPK training at WCoP2020
Going to WCoP 2020 in Cape Town?
Join the 1-day hands-on workshop "Open source PBPK modelling with the OSPSuite (PK-Sim® & MoBi®) for MIDD" hosted by Pharmetheus and Pharmacometrics Africa.
Read more and register here.
Register soon, only limited seats available!
Welcome Marie Olsson!
Welcome Siv Jönsson!
It is with great pleasure that we welcome Siv Jönsson to our team! Siv has been working in the pharmacokinetic, pharmacodynamic and pharmacometric areas in the pharmaceutical industry for a total of 5 years (Kabi Pharmacia, AstraZeneca), as a regulatory assessor at the Swedish Medical Products Agency for 9 years, and spent +10 years in academia as a senior lecturer and researcher dealing with methodological and applied pharmacometric projects. See her bio here.
We are active in the biosimilar area
Mechanism based pharmacometric analysis can be a powerful tool in the development of biosimilar drugs. Pharmetheus recently supported a client with evaluating the impact of study design and expected product differences on the power to demonstrate PK and PD similarity. Find out more in a recent paper by Ari Brekkan et al. AAPS J. 2019 Jul 8;21(5):85.
Request our services
If you are interested in our services, please fill out the form below.
How we work
Our way of working, with traceability and accountability from data programming to report delivery, is well adapted to, and highly compatible with, current regulatory requirements.